Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19.
Korper, Sixten 1; Weiss, Manfred 2; Zickler, Daniel 3; Wiesmann, Thomas 4; Zacharowski, Kai 5; Corman, Victor M. 6; Gruner, Beate 7; Ernst, Lucas 3; Spieth, Peter 8; Lepper, Philipp M. 9; Bentz, Martin 10; Zinn, Sebastian 5; Paul, Gregor 11; Kalbhenn, Johannes 12; Dollinger, Matthias M. 13; Rosenberger, Peter 14; Kirschning, Thomas 15; Thiele, Thomas 16; Appl, Thomas 1; Mayer, Benjamin 17; Schmidt, Michael 18; Drosten, Christian 6; Wulf, Hinnerk 4; Kruse, Jan Matthias 3; Jungwirth, Bettina 2; Seifried, Erhard 18; Schrezenmeier, Hubert 1; the CAPSID Clinical Trial Group
[Miscellaneous Article] Journal of Clinical Investigation. 131(20):e152264, October 15, 2021.

(Format: HTML, PDF)